The Forschungszentrum Dresden-Rossendorf Chooses NanoSight to Characterize Magnetic Nanoparticles
News Aug 18, 2010
The Institute for Radiopharmacy at the Forschungszentrum Dresden-Rossendorf is using NanoSight’s LM-20 nanoparticle characterization system to study magnetic nanoparticles for applications in cancer therapy.
The research team of Dr Holger Stephan is working to develop magnetic nanoparticles which can be applied in cancer therapy, preferably in combination with intracellular hyperthermia/ablation and endoradionuclide therapies. This requires nanoparticles to be very stable under physiological conditions and they should also avoid accumulation in the reticuloendothelial system.
Many techniques had been used to characterize the nanoparticles before Dr Stephan discovered the NanoSight system. These included Photon Correlation Spectroscopy (PCS), scanning electron microscopy (SEM) and ultra centrifugation. Nanoparticle Tracking Analysis, NTA, has been used to successfully follow the stability of different systems as a function of temperature in EDTA and different cell media.
There are three specific goals for measurement: First is to get information about the size distribution of nanoparticles and, more importantly, their stability under physiological relevant conditions, Next is to study the influence of nanoparticle surface modification on the size distribution finally to achieve structure-activity relationships for the nanoparticles on the cellular uptake behaviour (first step) and cancer tissue accumulation (second step).
Dr Stephan has described several advantages of the NanoSight LM-20 system. He says “the NanoSight provides reliable results on nanoparticles as small as 50nm. Sample handling and measurement is straightforward and experiments are performed more quickly than using PCS. The ability to work directly with relevant solutions removes another block to quickly understanding the behaviour of these magnetic nanoparticles and their ultimate use in treating cancers.”
“Our goal,” continues Dr Stephan “is to rewrite the medical paradigm, currently being “see and treat” and to make the future one of “detect and prevent.” By working on the combining of different therapeutic methodologies, we will provide synergetic medical effectiveness.”
UK Not Ready for Brexit’s Impact on Food, Report WarnsNews
Severe problems with the UK food system are likely unless issues are addressed, according to latest expert reportREAD MORE
Precision NanoSystems to Host Nanomedicines SymposiumNews
Precision NanoSystems holds its second annual nanomedicines symposium called Nanomedicines that will discuss the latest developments in nanomedicine research.READ MORE
High Serum Serotonin Levels Found in Blood of SIDS InfantsNews
Findings from NIH-funded study could provide basis for forensic SIDS test.READ MORE
Comments | 0 ADD COMMENT
9th Edition of International Conference on Analytical Chemistry
Mar 19 - Mar 20, 2018